Medical Care

Cancer Microbiome Testing - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

The global market for Cancer Microbiome Testing was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Cancer Microbiome Testing was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Cancer Microbiome Testing was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Cancer Microbiome Testing was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Cancer Microbiome Testing include CD Genomics, Eurofins Scientific, Illumina, Prescient Medicine Holding, Micronoma, Novogene, Oxford Nanopore Technologies, Pacific Biosciences and Qiagen, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Cancer Microbiome Testing, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Cancer Microbiome Testing by region & country, by Type, and by Application.
The Cancer Microbiome Testing market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Microbiome Testing.
Market Segmentation
By Company
CD Genomics
Eurofins Scientific
Illumina
Prescient Medicine Holding
Micronoma
Novogene
Oxford Nanopore Technologies
Pacific Biosciences
Qiagen
Therma Fisher Scientific
Segment by Type:
Next Generation Sequencing
Polymerase Chain Reaction
Segment by Application
Hospitals
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Cancer Microbiome Testing manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Cancer Microbiome Testing in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Cancer Microbiome Testing in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
1 Market Overview
1.1 Cancer Microbiome Testing Product Introduction
1.2 Global Cancer Microbiome Testing Market Size Forecast
1.3 Cancer Microbiome Testing Market Trends & Drivers
1.3.1 Cancer Microbiome Testing Industry Trends
1.3.2 Cancer Microbiome Testing Market Drivers & Opportunity
1.3.3 Cancer Microbiome Testing Market Challenges
1.3.4 Cancer Microbiome Testing Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Cancer Microbiome Testing Players Revenue Ranking (2023)
2.2 Global Cancer Microbiome Testing Revenue by Company (2019-2024)
2.3 Key Companies Cancer Microbiome Testing Manufacturing Base Distribution and Headquarters
2.4 Key Companies Cancer Microbiome Testing Product Offered
2.5 Key Companies Time to Begin Mass Production of Cancer Microbiome Testing
2.6 Cancer Microbiome Testing Market Competitive Analysis
2.6.1 Cancer Microbiome Testing Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Cancer Microbiome Testing Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Microbiome Testing as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Next Generation Sequencing
3.1.2 Polymerase Chain Reaction
3.2 Global Cancer Microbiome Testing Sales Value by Type
3.2.1 Global Cancer Microbiome Testing Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Cancer Microbiome Testing Sales Value, by Type (2019-2030)
3.2.3 Global Cancer Microbiome Testing Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospitals
4.1.2 Clinic
4.1.3 Others
4.2 Global Cancer Microbiome Testing Sales Value by Application
4.2.1 Global Cancer Microbiome Testing Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Cancer Microbiome Testing Sales Value, by Application (2019-2030)
4.2.3 Global Cancer Microbiome Testing Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Cancer Microbiome Testing Sales Value by Region
5.1.1 Global Cancer Microbiome Testing Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Cancer Microbiome Testing Sales Value by Region (2019-2024)
5.1.3 Global Cancer Microbiome Testing Sales Value by Region (2025-2030)
5.1.4 Global Cancer Microbiome Testing Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Cancer Microbiome Testing Sales Value, 2019-2030
5.2.2 North America Cancer Microbiome Testing Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Cancer Microbiome Testing Sales Value, 2019-2030
5.3.2 Europe Cancer Microbiome Testing Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Cancer Microbiome Testing Sales Value, 2019-2030
5.4.2 Asia Pacific Cancer Microbiome Testing Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Cancer Microbiome Testing Sales Value, 2019-2030
5.5.2 South America Cancer Microbiome Testing Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Cancer Microbiome Testing Sales Value, 2019-2030
5.6.2 Middle East & Africa Cancer Microbiome Testing Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Cancer Microbiome Testing Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Cancer Microbiome Testing Sales Value
6.3 United States
6.3.1 United States Cancer Microbiome Testing Sales Value, 2019-2030
6.3.2 United States Cancer Microbiome Testing Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Cancer Microbiome Testing Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Cancer Microbiome Testing Sales Value, 2019-2030
6.4.2 Europe Cancer Microbiome Testing Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Cancer Microbiome Testing Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Cancer Microbiome Testing Sales Value, 2019-2030
6.5.2 China Cancer Microbiome Testing Sales Value by Type (%), 2023 VS 2030
6.5.3 China Cancer Microbiome Testing Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Cancer Microbiome Testing Sales Value, 2019-2030
6.6.2 Japan Cancer Microbiome Testing Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Cancer Microbiome Testing Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Cancer Microbiome Testing Sales Value, 2019-2030
6.7.2 South Korea Cancer Microbiome Testing Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Cancer Microbiome Testing Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Cancer Microbiome Testing Sales Value, 2019-2030
6.8.2 Southeast Asia Cancer Microbiome Testing Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Cancer Microbiome Testing Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Cancer Microbiome Testing Sales Value, 2019-2030
6.9.2 India Cancer Microbiome Testing Sales Value by Type (%), 2023 VS 2030
6.9.3 India Cancer Microbiome Testing Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 CD Genomics
7.1.1 CD Genomics Profile
7.1.2 CD Genomics Main Business
7.1.3 CD Genomics Cancer Microbiome Testing Products, Services and Solutions
7.1.4 CD Genomics Cancer Microbiome Testing Revenue (US$ Million) & (2019-2024)
7.1.5 CD Genomics Recent Developments
7.2 Eurofins Scientific
7.2.1 Eurofins Scientific Profile
7.2.2 Eurofins Scientific Main Business
7.2.3 Eurofins Scientific Cancer Microbiome Testing Products, Services and Solutions
7.2.4 Eurofins Scientific Cancer Microbiome Testing Revenue (US$ Million) & (2019-2024)
7.2.5 Eurofins Scientific Recent Developments
7.3 Illumina
7.3.1 Illumina Profile
7.3.2 Illumina Main Business
7.3.3 Illumina Cancer Microbiome Testing Products, Services and Solutions
7.3.4 Illumina Cancer Microbiome Testing Revenue (US$ Million) & (2019-2024)
7.3.5 Prescient Medicine Holding Recent Developments
7.4 Prescient Medicine Holding
7.4.1 Prescient Medicine Holding Profile
7.4.2 Prescient Medicine Holding Main Business
7.4.3 Prescient Medicine Holding Cancer Microbiome Testing Products, Services and Solutions
7.4.4 Prescient Medicine Holding Cancer Microbiome Testing Revenue (US$ Million) & (2019-2024)
7.4.5 Prescient Medicine Holding Recent Developments
7.5 Micronoma
7.5.1 Micronoma Profile
7.5.2 Micronoma Main Business
7.5.3 Micronoma Cancer Microbiome Testing Products, Services and Solutions
7.5.4 Micronoma Cancer Microbiome Testing Revenue (US$ Million) & (2019-2024)
7.5.5 Micronoma Recent Developments
7.6 Novogene
7.6.1 Novogene Profile
7.6.2 Novogene Main Business
7.6.3 Novogene Cancer Microbiome Testing Products, Services and Solutions
7.6.4 Novogene Cancer Microbiome Testing Revenue (US$ Million) & (2019-2024)
7.6.5 Novogene Recent Developments
7.7 Oxford Nanopore Technologies
7.7.1 Oxford Nanopore Technologies Profile
7.7.2 Oxford Nanopore Technologies Main Business
7.7.3 Oxford Nanopore Technologies Cancer Microbiome Testing Products, Services and Solutions
7.7.4 Oxford Nanopore Technologies Cancer Microbiome Testing Revenue (US$ Million) & (2019-2024)
7.7.5 Oxford Nanopore Technologies Recent Developments
7.8 Pacific Biosciences
7.8.1 Pacific Biosciences Profile
7.8.2 Pacific Biosciences Main Business
7.8.3 Pacific Biosciences Cancer Microbiome Testing Products, Services and Solutions
7.8.4 Pacific Biosciences Cancer Microbiome Testing Revenue (US$ Million) & (2019-2024)
7.8.5 Pacific Biosciences Recent Developments
7.9 Qiagen
7.9.1 Qiagen Profile
7.9.2 Qiagen Main Business
7.9.3 Qiagen Cancer Microbiome Testing Products, Services and Solutions
7.9.4 Qiagen Cancer Microbiome Testing Revenue (US$ Million) & (2019-2024)
7.9.5 Qiagen Recent Developments
7.10 Therma Fisher Scientific
7.10.1 Therma Fisher Scientific Profile
7.10.2 Therma Fisher Scientific Main Business
7.10.3 Therma Fisher Scientific Cancer Microbiome Testing Products, Services and Solutions
7.10.4 Therma Fisher Scientific Cancer Microbiome Testing Revenue (US$ Million) & (2019-2024)
7.10.5 Therma Fisher Scientific Recent Developments
8 Industry Chain Analysis
8.1 Cancer Microbiome Testing Industrial Chain
8.2 Cancer Microbiome Testing Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Cancer Microbiome Testing Sales Model
8.5.2 Sales Channel
8.5.3 Cancer Microbiome Testing Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Cancer Microbiome Testing Market Trends
Table 2. Cancer Microbiome Testing Market Drivers & Opportunity
Table 3. Cancer Microbiome Testing Market Challenges
Table 4. Cancer Microbiome Testing Market Restraints
Table 5. Global Cancer Microbiome Testing Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Cancer Microbiome Testing Revenue Market Share by Company (2019-2024)
Table 7. Key Companies Cancer Microbiome Testing Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Cancer Microbiome Testing Product Type
Table 9. Key Companies Time to Begin Mass Production of Cancer Microbiome Testing
Table 10. Global Cancer Microbiome Testing Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Microbiome Testing as of 2023)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Cancer Microbiome Testing Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global Cancer Microbiome Testing Sales Value by Type (2019-2024) & (US$ Million)
Table 15. Global Cancer Microbiome Testing Sales Value by Type (2025-2030) & (US$ Million)
Table 16. Global Cancer Microbiome Testing Sales Market Share in Value by Type (2019-2024) & (%)
Table 17. Global Cancer Microbiome Testing Sales Market Share in Value by Type (2025-2030) & (%)
Table 18. Global Cancer Microbiome Testing Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global Cancer Microbiome Testing Sales Value by Application (2019-2024) & (US$ Million)
Table 20. Global Cancer Microbiome Testing Sales Value by Application (2025-2030) & (US$ Million)
Table 21. Global Cancer Microbiome Testing Sales Market Share in Value by Application (2019-2024) & (%)
Table 22. Global Cancer Microbiome Testing Sales Market Share in Value by Application (2025-2030) & (%)
Table 23. Global Cancer Microbiome Testing Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 24. Global Cancer Microbiome Testing Sales Value by Region (2019-2024) & (US$ Million)
Table 25. Global Cancer Microbiome Testing Sales Value by Region (2025-2030) & (US$ Million)
Table 26. Global Cancer Microbiome Testing Sales Value by Region (2019-2024) & (%)
Table 27. Global Cancer Microbiome Testing Sales Value by Region (2025-2030) & (%)
Table 28. Key Countries/Regions Cancer Microbiome Testing Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 29. Key Countries/Regions Cancer Microbiome Testing Sales Value, (2019-2024) & (US$ Million)
Table 30. Key Countries/Regions Cancer Microbiome Testing Sales Value, (2025-2030) & (US$ Million)
Table 31. CD Genomics Basic Information List
Table 32. CD Genomics Description and Business Overview
Table 33. CD Genomics Cancer Microbiome Testing Products, Services and Solutions
Table 34. Revenue (US$ Million) in Cancer Microbiome Testing Business of CD Genomics (2019-2024)
Table 35. CD Genomics Recent Developments
Table 36. Eurofins Scientific Basic Information List
Table 37. Eurofins Scientific Description and Business Overview
Table 38. Eurofins Scientific Cancer Microbiome Testing Products, Services and Solutions
Table 39. Revenue (US$ Million) in Cancer Microbiome Testing Business of Eurofins Scientific (2019-2024)
Table 40. Eurofins Scientific Recent Developments
Table 41. Illumina Basic Information List
Table 42. Illumina Description and Business Overview
Table 43. Illumina Cancer Microbiome Testing Products, Services and Solutions
Table 44. Revenue (US$ Million) in Cancer Microbiome Testing Business of Illumina (2019-2024)
Table 45. Illumina Recent Developments
Table 46. Prescient Medicine Holding Basic Information List
Table 47. Prescient Medicine Holding Description and Business Overview
Table 48. Prescient Medicine Holding Cancer Microbiome Testing Products, Services and Solutions
Table 49. Revenue (US$ Million) in Cancer Microbiome Testing Business of Prescient Medicine Holding (2019-2024)
Table 50. Prescient Medicine Holding Recent Developments
Table 51. Micronoma Basic Information List
Table 52. Micronoma Description and Business Overview
Table 53. Micronoma Cancer Microbiome Testing Products, Services and Solutions
Table 54. Revenue (US$ Million) in Cancer Microbiome Testing Business of Micronoma (2019-2024)
Table 55. Micronoma Recent Developments
Table 56. Novogene Basic Information List
Table 57. Novogene Description and Business Overview
Table 58. Novogene Cancer Microbiome Testing Products, Services and Solutions
Table 59. Revenue (US$ Million) in Cancer Microbiome Testing Business of Novogene (2019-2024)
Table 60. Novogene Recent Developments
Table 61. Oxford Nanopore Technologies Basic Information List
Table 62. Oxford Nanopore Technologies Description and Business Overview
Table 63. Oxford Nanopore Technologies Cancer Microbiome Testing Products, Services and Solutions
Table 64. Revenue (US$ Million) in Cancer Microbiome Testing Business of Oxford Nanopore Technologies (2019-2024)
Table 65. Oxford Nanopore Technologies Recent Developments
Table 66. Pacific Biosciences Basic Information List
Table 67. Pacific Biosciences Description and Business Overview
Table 68. Pacific Biosciences Cancer Microbiome Testing Products, Services and Solutions
Table 69. Revenue (US$ Million) in Cancer Microbiome Testing Business of Pacific Biosciences (2019-2024)
Table 70. Pacific Biosciences Recent Developments
Table 71. Qiagen Basic Information List
Table 72. Qiagen Description and Business Overview
Table 73. Qiagen Cancer Microbiome Testing Products, Services and Solutions
Table 74. Revenue (US$ Million) in Cancer Microbiome Testing Business of Qiagen (2019-2024)
Table 75. Qiagen Recent Developments
Table 76. Therma Fisher Scientific Basic Information List
Table 77. Therma Fisher Scientific Description and Business Overview
Table 78. Therma Fisher Scientific Cancer Microbiome Testing Products, Services and Solutions
Table 79. Revenue (US$ Million) in Cancer Microbiome Testing Business of Therma Fisher Scientific (2019-2024)
Table 80. Therma Fisher Scientific Recent Developments
Table 81. Key Raw Materials Lists
Table 82. Raw Materials Key Suppliers Lists
Table 83. Cancer Microbiome Testing Downstream Customers
Table 84. Cancer Microbiome Testing Distributors List
Table 85. Research Programs/Design for This Report
Table 86. Key Data Information from Secondary Sources
Table 87. Key Data Information from Primary Sources
Table 88. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Cancer Microbiome Testing Product Picture
Figure 2. Global Cancer Microbiome Testing Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Cancer Microbiome Testing Sales Value (2019-2030) & (US$ Million)
Figure 4. Cancer Microbiome Testing Report Years Considered
Figure 5. Global Cancer Microbiome Testing Players Revenue Ranking (2023) & (US$ Million)
Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Cancer Microbiome Testing Revenue in 2023
Figure 7. Cancer Microbiome Testing Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. Next Generation Sequencing Picture
Figure 9. Polymerase Chain Reaction Picture
Figure 10. Global Cancer Microbiome Testing Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 11. Global Cancer Microbiome Testing Sales Value Market Share by Type, 2023 & 2030
Figure 12. Product Picture of Hospitals
Figure 13. Product Picture of Clinic
Figure 14. Product Picture of Others
Figure 15. Global Cancer Microbiome Testing Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 16. Global Cancer Microbiome Testing Sales Value Market Share by Application, 2023 & 2030
Figure 17. North America Cancer Microbiome Testing Sales Value (2019-2030) & (US$ Million)
Figure 18. North America Cancer Microbiome Testing Sales Value by Country (%), 2023 VS 2030
Figure 19. Europe Cancer Microbiome Testing Sales Value (2019-2030) & (US$ Million)
Figure 20. Europe Cancer Microbiome Testing Sales Value by Country (%), 2023 VS 2030
Figure 21. Asia Pacific Cancer Microbiome Testing Sales Value (2019-2030) & (US$ Million)
Figure 22. Asia Pacific Cancer Microbiome Testing Sales Value by Country (%), 2023 VS 2030
Figure 23. South America Cancer Microbiome Testing Sales Value (2019-2030) & (US$ Million)
Figure 24. South America Cancer Microbiome Testing Sales Value by Country (%), 2023 VS 2030
Figure 25. Middle East & Africa Cancer Microbiome Testing Sales Value (2019-2030) & (US$ Million)
Figure 26. Middle East & Africa Cancer Microbiome Testing Sales Value by Country (%), 2023 VS 2030
Figure 27. Key Countries/Regions Cancer Microbiome Testing Sales Value (%), (2019-2030)
Figure 28. United States Cancer Microbiome Testing Sales Value, (2019-2030) & (US$ Million)
Figure 29. United States Cancer Microbiome Testing Sales Value by Type (%), 2023 VS 2030
Figure 30. United States Cancer Microbiome Testing Sales Value by Application (%), 2023 VS 2030
Figure 31. Europe Cancer Microbiome Testing Sales Value, (2019-2030) & (US$ Million)
Figure 32. Europe Cancer Microbiome Testing Sales Value by Type (%), 2023 VS 2030
Figure 33. Europe Cancer Microbiome Testing Sales Value by Application (%), 2023 VS 2030
Figure 34. China Cancer Microbiome Testing Sales Value, (2019-2030) & (US$ Million)
Figure 35. China Cancer Microbiome Testing Sales Value by Type (%), 2023 VS 2030
Figure 36. China Cancer Microbiome Testing Sales Value by Application (%), 2023 VS 2030
Figure 37. Japan Cancer Microbiome Testing Sales Value, (2019-2030) & (US$ Million)
Figure 38. Japan Cancer Microbiome Testing Sales Value by Type (%), 2023 VS 2030
Figure 39. Japan Cancer Microbiome Testing Sales Value by Application (%), 2023 VS 2030
Figure 40. South Korea Cancer Microbiome Testing Sales Value, (2019-2030) & (US$ Million)
Figure 41. South Korea Cancer Microbiome Testing Sales Value by Type (%), 2023 VS 2030
Figure 42. South Korea Cancer Microbiome Testing Sales Value by Application (%), 2023 VS 2030
Figure 43. Southeast Asia Cancer Microbiome Testing Sales Value, (2019-2030) & (US$ Million)
Figure 44. Southeast Asia Cancer Microbiome Testing Sales Value by Type (%), 2023 VS 2030
Figure 45. Southeast Asia Cancer Microbiome Testing Sales Value by Application (%), 2023 VS 2030
Figure 46. India Cancer Microbiome Testing Sales Value, (2019-2030) & (US$ Million)
Figure 47. India Cancer Microbiome Testing Sales Value by Type (%), 2023 VS 2030
Figure 48. India Cancer Microbiome Testing Sales Value by Application (%), 2023 VS 2030
Figure 49. Cancer Microbiome Testing Industrial Chain
Figure 50. Cancer Microbiome Testing Manufacturing Cost Structure
Figure 51. Channels of Distribution (Direct Sales, and Distribution)
Figure 52. Bottom-up and Top-down Approaches for This Report
Figure 53. Data Triangulation
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies